Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
0.2047
-0.0049 (-2.34%)
At close: Apr 25, 2025, 4:00 PM
0.2006
-0.0041 (-2.00%)
After-hours: Apr 25, 2025, 7:43 PM EDT
Palatin Technologies Revenue
Palatin Technologies had revenue of $350.00K in the twelve months ending December 31, 2024, down -95.07% year-over-year. In the fiscal year ending June 30, 2024, Palatin Technologies had annual revenue of $4.49M, down -7.49%.
Revenue (ttm)
$350.00K
Revenue Growth
-95.07%
P/S Ratio
10.79
Revenue / Employee
$11,667
Employees
30
Market Cap
5.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 4.49M | -363.59K | -7.49% |
| Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
| Jun 30, 2022 | 1.47M | 1.66M | -878.62% |
| Jun 30, 2021 | -188.60K | -306.59K | -259.84% |
| Jun 30, 2020 | 117.99K | -60.18M | -99.80% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
PTN News
- 10 days ago - Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - PRNewsWire
- 13 days ago - Palatin Appeals NYSE American Notice of Delisting - PRNewsWire
- 17 days ago - NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
- 17 days ago - Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal - PRNewsWire
- 17 days ago - Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting - PRNewsWire
- 27 days ago - Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - PRNewsWire
- 4 weeks ago - Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 - PRNewsWire
- 4 weeks ago - Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency - PRNewsWire